The evolution of the biomedical paradigm in oncology: Implications for cancer therapy

Advances in Experimental Medicine and Biology

Volumn 610, Issue , 2008, Pages 5-18

  Corbellini, Gilberto ^a   Preti, Chiara ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BEVACIZUMAB; COLONY STIMULATING FACTOR; DENILEUKIN DIFTITOX; GEFITINIB; HEPATITIS B VACCINE; IMATINIB; INTERFERON; INTERLEUKIN 2; METHOTREXATE; ONCOTYPE DX; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CANCER GROWTH; CANCER THERAPY; MEDICAL TECHNOLOGY; PHILOSOPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; EVOLUTION; FINANCIAL MANAGEMENT; HISTORY; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NEOPLASM; ONCOLOGY; PATHOLOGY; THEORETICAL MODEL;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; EVOLUTION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASMS; RESEARCH SUPPORT AS TOPIC;

EID: 47949091725     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-73898-7_2     Document Type: Review

References (52)

1. Anderson, G. R. (2001) Genomic instability and cancer. Current Science. 81, 501-507.
2. Armitage, P. and Doll, R. (1954) The Age Distribution of Cancer and a Multistage Theory of Carcinogenesis. British Journal of Cancer. 8, 9.
3. Balmain, A. (2001) Cancer genetics: from Boveri and Mendel to microarrays. Nature Reviews Cancer 1, 77-82.
4. Berenbluem, I. and Shubik, P. (1949) An Experimental Study of the Initiating Stage of Carcinogenesis, and a Re-Examination of the Somatic Cell Mutation Theory of Cancer. British Journal of Cancer. 3, 109-18.
5. Berenblum, I. and Shubik, P. (1947) A New, Quantitative Approach to the Study of the Stages of Chemical Carcinogenesis in the Mouse's Skin. British Journal of Cancer 1, 383-91.
6. Boveri, T. H. (1914) Zur Frage der Enstehung maligner Tumoren. Gustav Fisher, Jena.
7. Breivik, J. and Gaudernack, G. (1999) Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv. Cancer Research 76, 187-212.
8. Burdette, W. J. (1955) The Significance of Mutation in Relation to the Origin of Tumors: A Review. Cancer Res 15, 201-226. Cahill, D. P.; Kinzler, K.W.; Vogelstein, B., and Lengauer, C. (1999) Genetic instability and Darwinian selection in tumors. Trends Cell Biol. 12, M57-60.
9. Comings, D. E. (1973) A General Theory of Carcinogenesis. Proc. Natl. Acad. Sci. 70, 3324-28.
10. Corbellini G. (2007) EBM. Evolution Based Medicine. Il darwinismo nelle scienze biomediche.
11. Laterza, Roma-Bari. Dobzhansky, T. (1973) Nothing in Biology Makes Sense Except in the Light of Evolution. The American Biology Teacher 35, 125-129.
12. Drews, J. (2006) Case histories, magic bullets and the state of drug discovery. Nature Rev. Drug Discovery 5, 635-640.
13. Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
14. Ferrara, N.; Hillan, K. J.; Gerber, H. P. and Novotny, W. (2004) Discovery and development of bevacizumab, and anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery 3, 391-400.
15. Folkman, J. and Kalluri, R. (2004) Cancer without disease. Nature 427, 787.
16. Foulds, L. (1949) Mammary tumors in hybrid mice; growth and progression of spontaneous tumors. British Journal of Cancer 3, 345-75.
17. Foulds, L. (1954) The experimental study of tumor progression: a review. Cancer Research 14, 327-339.
18. Foulds, L. (1956) The histologic analysis of mammary tumors of mice. 2. The histology of respon- siveness and progression - The origins of tumors. Journal of the National Cancer Institute 17, 713-756.
19. Foulds, L. (1958) The natural history of cancer. Journal of Chronic Diseases 8, 2-37.
20. Foulds, L. (1969) Neoplastic Development. Academic Press, New York.
21. Friend, S. H.; Bernards, R.; Rogelj, S., et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643-46.
22. Gardner, M. B. (1994) The Virus Cancer Program of the 1970s: a personal and retrospective view. Laboratory Animals Science 44, 101-13.
23. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
24. Harris, H.; Miller, O. J.; Klein, G.; Worst, P. and, Tachibana, T. (1969) Suppression of malignancy by cell fusion. Nature, 223, 363-8.
25. Hasegawa, Y.; Ando, Y.; Ando, M.; Hashimoto, N.; Imaizumi, K. and Shimokata, K. (2006) Pharmacogenetic Approach for Cancer Treatment-Tailored Medicine in Practice. Ann. N. Y. Acad. Sci. 1086, 223-232.
26. Hochedlinger, K.; Blelloch, R.; Brennan, C.; Yamada, Y.; Kim, M.; Chin, L. and Jaenisch, R. (2004) Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18, 1875-1885.
27. Horrobin, D. F. (2003) Modern biomedical research: an internally self-consistent universe with little contact with medical reality. Nature Rev. Drug Discovery 2, 151-154.
28. Huebner, R. J. and Todaro, G. J. (1969) Oncogenes of RNA tumor viruses as determinants of Cancer, Proc. Natl. Acad. Sci. 64, 1087-94.
29. Knudson, A. G. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. 68, 820-823.
30. Knudson, A. G. (1971) Mutation and Cancer: Statistical Study of Retinoblastoma. Proc. Nat. Acad. Sci. 68, 820-23.
31. Knudson, A. G. (1983) Model hereditary cancers of man. Pro. Nucleic Acid Res. Mol. Biol. 29, 17-25.
32. Knudson, A. G. (1985) Hereditary Cancer, Oncogenes, and Antioncogenes. Cancer Research, 45, 1437-43.
33. Knudson, A. G. (2005) A personal 60-Year Tour of Genetics and Medicine. Annu. Rev. Genomics Hum. Genet. 6, 1-14.
34. Koufos, A.; Hansen, M. F.; Copeland, N. G.; Jenkins, N. A.; Lampkin, B. C. and Cavenee, W. K. (1986) Loss of heterozygosity in three embryonal tumors suggests a common pathogenetic mechanism. Nature 316, 330-34.
35. Leaf, C. (2004) Why we're losing the war on cancer (and how to win it). Fortune 149(6), 76-82, 84-6, 88.
36. Michor, F.; Iwasa, Y. and Nowak, M. A. (2004) Dynamics of cancer progression. Nature Review Cancer, 4, 197-205.
37. Michor, F.; Nowak, M. A. and Iwasa, Y. (2006) Evolution of resistance to cancer therapy. Current Pharmaceutical Design 12, 261-271.
38. Moss, L. (2003) What Genes Can't Do. The MIT Press, Cambridge (MA).
39. Nowell, P. C. (1976) The clonal evolution of tumor cell populations. Science 194, 23-8.
40. Rous, P. (1943) The Nearer Causes of Cancer JAMA 122, 573-81.
41. Porter, R. (1997) The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present. Harper Collins, London.
42. Schimke, R. T.; Kaufman, R. J.; Alt, F. W. and Kellems, R. F. (1978) Gene amplification and drug resistance in cultured murine cells. Science 202, 1051-5.
43. Searls, D. B. (2003) Pharmacophylogenomics: genes, evolution and drug targets. Nature Rev. Drug Discovery 2, 613-623.
44. Smithers, D. W. (1962) An attack on cytologism. The Lancet 1, 493-9.
45. Stehelin, D.; Varmus, H. E. and Bishop, M. J. (1976) DNA related to the Transforming Gene(s) of Avian Sarcoma Viruses Is Present in Normal Avian DNA. Nature 260, 170-3.
46. Temin, H. M. (1971) The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J Natl Cancer Inst. 46(2), 3-7.
47. Thagard, P. (1999) How Scientists Explain Disease. Princeton University Press, Princeton.
48. Varmus, H. (2006) The New Era in Cancer Research. Science 312, 1162-1165.
49. Vineis, P. and Berwick, M. (2006) The population dynamics of cancer: a Darwinian perspective. Int. J. Epidemiol. 35, 1151-9.
50. Weinberg, R. (2006) The Biology of Cancer. Garland Science, New York.
51. Weiss, L. (2000). Cancer cell heterogeneity. Cancer and Metastasis Reviews 19, 345-350.
52. Wicha, M. S.; Liu, S. and Dontu, G. (2006). Cancer Stem Cells: An Old Idea - A Paradigm Shift. Cancer Research 66, 1883-1890.